Fmr LLC Purchases New Stake in Upstream Bio, Inc. (NASDAQ:UPB)

FMR LLC purchased a new position in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 7,176,187 shares of the company's stock, valued at approximately $117,977,000. FMR LLC owned 13.39% of Upstream Bio at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. US Bancorp DE purchased a new position in Upstream Bio during the fourth quarter worth approximately $27,000. Corebridge Financial Inc. acquired a new stake in Upstream Bio in the 4th quarter valued at $142,000. Wells Fargo & Company MN acquired a new position in Upstream Bio during the fourth quarter worth $149,000. Rhumbline Advisers purchased a new position in Upstream Bio during the fourth quarter valued at $275,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Upstream Bio during the fourth quarter worth about $607,000.

Upstream Bio Trading Up 4.3 %

Upstream Bio stock traded up $0.36 during midday trading on Friday, reaching $8.78. The company had a trading volume of 315,158 shares, compared to its average volume of 325,012. Upstream Bio, Inc. has a 12-month low of $5.14 and a 12-month high of $29.46. The business has a fifty day moving average of $7.71.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.